Investing News NetworkApril 08, 2024Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the 'Company' or 'Sona') announces that it has been approved for funding totaling approximately $40,000 to support the development of its intellectual property portfolio.The Company is receiving advisory services and up to $24,894 in funding from the National Research Council of Canada Industrial Research Assistance Program ('NRC IRAP') IP Assist program to support the development of an intellectual property strategy for Sona's proprietary gold nanorods for novel targeted drug delivery concepts with a view to securing new patents.The Company was also approved for funding of approximately $15,000 by Springboard Atlantic under its Atlantic IP Advantage program to implement its IP strategy.

投资新闻网2024年4月8日，SONA Nanotech Inc.（CSE:SONA）（OTCQB:SNANF）（“公司”或“SONA”）宣布，其已被批准提供总计约40000美元的资金，以支持其知识产权投资组合的发展。该公司正在接受加拿大国家研究委员会工业研究援助计划（“NRC IRAP”）知识产权援助计划的咨询服务和高达24894美元的资金，以支持Sona专有金纳米棒的知识产权战略的制定，用于新的靶向药物输送概念，以获得新的专利。Springboard Atlantic根据其Atlantic IP Advantage计划批准了该公司约15000美元的资金，以实施其IP战略。

Springboard Atlantic is designed to grow Atlantic Canada's innovation economy through collaboration among post-secondary institutions and industry. This funding will support the final drafting and filing of a provisional patent for a novel targeted drug delivery concept being developed by the Company.Sona CEO David Regan commented, 'We appreciate the support of both NRC IRAP and Springboard Atlantic under its Atlantic IP Advantage program.

Springboard Atlantic旨在通过高等教育机构和行业之间的合作来发展加拿大大西洋的创新经济。这笔资金将支持该公司正在开发的新型靶向药物递送概念的临时专利的最终起草和提交。Sona首席执行官大卫·里根（DavidRegan）评论道，“我们感谢NRC IRAP和Springboard Atlantic在其大西洋知识产权优势计划下的支持。

This funding will support the Company in its work developing intellectual property around the significant investments it is making locally in the research and development of cancer applications for our proprietary, uniquely biocompatible gold nanorod manufacturing technology.'Contact:David Regan, CEO+1-902-536-1932 david@sonanano.comAbout Sona Nanotech Inc.Sona Nanotech, a nanotechnology life sciences company, is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors.

这笔资金将支持该公司围绕其在当地为我们专有的，独特的生物相容性金纳米棒制造技术的癌症应用研究和开发方面的重大投资，开发知识产权。”联系人：David Regan，CEO+1-902-536-1932david@sonanano.comAboutSona Nanotech Inc.Sona Nanotech是一家纳米技术生命科学公司，正在开发靶向热疗™，这是一种光热癌症疗法，它使用治疗热来治疗实体癌肿瘤。

The heat is delivered to tumors by .

热量通过传递给肿瘤。